Scripps Research, recently ranked as the most influential institution in the world for innovation by Nature Index, selected Repurpose.AI to leverage their ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine in a quest to discover drug candidates to treat COVID-19. This selection was not coincidental: the technology was used to successfully discover REP-001, REP—002, and REP-003—all Phase II/III ready small molecule assets for the treatment of gastric, neurological, and weight disorders.
TrialSite News provides a breakdown for the TrialSite Network.
What is Repurpose.AI?
They are a portfolio company of Nex Cubed, a digital health venture. They harness the predictive prowess of artificial intelligence and machine learning with its ActivPred AI Drug Discovery Platform to discover drugs that may be repurposed to serve as therapeutics to treat patients suffering from COVID-19. The drugs that Repurpose.AI discovers for COVID-19 can enter clinical trials in as little as several months.
What is Repurpose. AI’s Drug Library?
It is a library composed of approximately 4,000 drug compounds that have been approved fo...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).